ANDELA v. University of Miami

692 F. Supp. 2d 1356, 2010 U.S. Dist. LEXIS 20432, 2010 WL 768947
CourtDistrict Court, S.D. Florida
DecidedMarch 8, 2010
DocketCase 09-21723-CIV
StatusPublished
Cited by8 cases

This text of 692 F. Supp. 2d 1356 (ANDELA v. University of Miami) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
ANDELA v. University of Miami, 692 F. Supp. 2d 1356, 2010 U.S. Dist. LEXIS 20432, 2010 WL 768947 (S.D. Fla. 2010).

Opinion

ORDER GRANTING IN PART UNIVERSITY OF MIAMI’S MOTION TO DISMISS OR, IN THE ALTERNATIVE, FOR SUMMARY JUDGMENT; GRANTING IN PART UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL’S MOTION TO DISMISS OR, IN THE ALTERNATIVE, FOR SUMMARY JUDGMENT

K. MICHAEL MOORE, District Judge.

THIS CAUSE came before the Court upon Defendant University of Miami’s Motion to Dismiss or, in the Alternative, for Summary Judgment (dkt. # 14) and Defendant University of North Carolina at Chapel Hill’s Motion to Dismiss or, in the Alternative, for Summary Judgment (dkt. # 25). Plaintiff filed Responses (dkt. #’s 24, 31) and Defendants filed Replies (dkt. #’s 28, 38).

UPON CONSIDERATION of the Motions, the Responses, the Replies, the pertinent portions of the record, and being otherwise fully advised in the premises, the Court enters the following Order.

I. BACKGROUND

This case arises out of pro se Plaintiff Valentine B. Andela’s (“Andela”) employment with Defendant University of Miami (“UM”) and his subsequent termination. Andela is a physician-scientist from Cameroon, Africa, whose area of study is translational cancer research and international technology transfer to Africa. Andela was employed by UM from June of 2005 to September 25, 2006, as a post-doctoral associate in the Viral Oncology program at UM’s Sylvester Comprehensive Care Center (the “Sylvester Center”). Throughout his employment as a post-doctoral associate, Andela worked in the laboratory of Dr. William J. Harrington, Jr. (“Harrington”). Andela was also enrolled in UM’s Master of Art in International Administration (“MALA”) program from January of 2006 to October of 2007.

A. Andela’s Employment with UM

Andela is an internationally recognized cancer researcher who is black and a native of Cameroon. ALJ Recommended Order at 6 (dkt. # 14-8); see also Am. Compl. ¶ 2. In 1999, he received his Ph.D. from the University of Yaounde I in Cameroon. ALJ Recommended Order at 7 (dkt. # 14-8). Andela spent the next five years working as a post-doctoral fellow at the University of Rochester Medical Center in Rochester, New York. Id. In June of 2005, Andela began working as a post-doctoral associate in the Viral Oncology Program at the Sylvester Center. Id. The Sylvester Center serves as the hub for cancer-related research, diagnosis, and treatment at UM’s School of Medicine. Id. Harrington was in charge of the Viral Oncology program throughout Andela’s employment and ran a cancer-research laboratory focused on the therapeutic targeting of NFkappaB signaling in Epstein Barr Virus related to Burkitt’s Lymphomas and developing international research programs. Id. at 9. Harrington’s lab was funded entirely by research grants including grants from the National Institutes of Health (“NIH”), the Leukemia Society, and the State of Florida. Id.

*1362 In June of 2005, Harrington personally interviewed Andela and offered him a postdoctoral position in his lab. Id. at 10. As a post-doctoral associate, Andela was the “senior lab person” working under Harrington’s supervision. Id. Andela alleges that he “accepted the position of a postdoctoral associate with the understanding that he would be moving up to an independent (faculty) position within a year-which is standard expectation of someone with over 5 years of successful post-doctoral experience-and would be pursing his primary interest in translational cancer research (targeted therapeutics of NFkappaB signaling in cancer) and international development and technology transfer to Africa.” Am. Compl. ¶ 35. Harrington and Andela initially enjoyed a cordial working and social relationship. ALJ Recommended Order at 10(dkt. # 14-8).

During the first several months of his employment, Andela engaged in research involving NFkappaB signaling. Id. at 12. Harrington was impressed with Andela’s work in the lab and with an article Andela had published in the East African Medical Journal. Id. Andela also contributed to the preparation of a successful NIH grant submitted by Harrington on September 1, 2005. Id. The NIH grant involved funding for a project in collaboration with researchers in Brazil and at the University of North Carolina at Chapel Hill (“UNC”). Id. The project involved research on Burkitt’s Lymphomas, Epstein Barr virus, and their relationship to NFkappaB. Id. at 13. The grant application was based on work that was done prior to Andela’s employment under Harrington. Id. Listed as key personnel on the grant application were: Harrington; Iguaracyra Aruajo, M.D., of Brazil; Jose Barreto, M.D., of Brazil; Carlos Brites, M.D., Ph.D., of Brazil (collectively, the “Brazilian Investigators”); Dirk Dittmer, Ph.D., of UNC (“Dittmer”); and Isildinha Reis, Ph.D., of UM. Id. Also included on the grant was a statement made concerning the anticipated role of Andela in the project. Id. The statement indicated that Andela would be in charge of the day-to-day aspects of Harrington’s work including receiving research samples shipped from Brazil and forwarding them to Dittmer at UNC, performing cell cultures, preparing DNA and RNA, and analyzing other research samples. Id. at 14.

Andela alleges, however, that the NIH grant also incorporated a commitment between Harrington’s lab and researchers in Cameroon. Am. Compl. ¶ 37. Andela alleges that sometime between July and August 2005, a commitment was made between himself, Harrington, the chair and vice-chair of the national cancer control program in Cameroon, and the vice dean in-charge of research and international cooperation at the University of Yaounde I, to collaborate and develop an international research program on Burkitt’s Lymphoma. Id. Andela further alleges that Harrington represented to him that the NIH grant application incorporated the research commitments in Cameroon and that once the funding came through, Andela would independently develop the research program in Africa and would receive a faculty position and a dedicated research technician. Id.

In the fall of 2005, Harrington and Andela discussed the prospect of Andela researching Epstein-Barr virus (“EBV”) microRNAs, a novel area of research. ALJ Recommended Order at 14 (dkt. # 14-8). With Harrington’s approval, Andela began researching EBV microRNAs, a project that consumed most of his work time during his employment with UM. Id. Andela’s project included helping draft a manuscript detailing the findings of *1363 his research. Id. In November of 2005, Andela advised Harrington that he was considering participating in a clinical residency program at UM’s Jackson Memorial Medical Center (“Jackson Memorial”). Id. at 15. Harrington wrote Andela a letter of recommendation praising him for exceeding expectations and personally called Stephen Symes, M.D. (“Symes”), who was the head of Jackson Memorial’s staff program at the time, to recommend Andela. Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
692 F. Supp. 2d 1356, 2010 U.S. Dist. LEXIS 20432, 2010 WL 768947, Counsel Stack Legal Research, https://law.counselstack.com/opinion/andela-v-university-of-miami-flsd-2010.